Visão geral da empresa
A biopharmaceutical entity, Alkermes plc engages in the research, development, and commercialization of pharmaceutical products designed to address unmet medical needs within specific therapeutic areas across the United States, Ireland, and international markets. The company operates within the Healthcare sector, specifically classified under the industry of Drug Manufacturers - Specialty & Generic, which signifies a focus on niche medical solutions rather than broad commodity pharmaceuticals. The firm maintains a significant operational scale, employing 2.050 individuals to support its commercial portfolio and research initiatives. With a total market capitalization of $5.79B and annual revenue of $1.48B, the company holds a substantial position in the market, indicating a large-cap status that provides liquidity and stability typical of established healthcare players.
Saúde financeira
The company reported a revenue of $1.48B for the trailing twelve months, generating a net income of $241.66M and an EBITDA of $281.12M, highlighting a cost structure where operating expenses reduce pre-tax earnings by approximately $40M. However, the financial picture becomes more complex when examining the free cash flow, which stands at -$363.09M, indicating a significant cash burn that impacts the company's immediate financial flexibility and ability to fund operations without external financing. Profitability efficiency is demonstrated through a gross margin of 86.7%, reflecting the high value of proprietary products before operating costs, while the operating margin of 15.1% and profit margin of 16.4% show that overheads and taxes consume a considerable portion of the gross revenue. The balance sheet presents a conservative profile with total cash assets of $588.21M significantly outweighing total debt of $70.00M, supported by a low debt-to-equity ratio of 3.85. Short-term liquidity is robust, evidenced by a current ratio of 3.55, suggesting the company possesses more than three times the current assets necessary to cover its current liabilities. Furthermore, the return on equity of 14.7% and return on assets of 7.0% reveal that management is generating substantial returns on shareholder capital relative to the asset base employed.
Avaliação de valorização
Valuation metrics for Alkermes plc indicate a trailing P/E ratio of 24.31 compared to a forward P/E of 17.44, suggesting that the market expects a significant expansion in earnings that would lower the multiple from current levels to the projected forward multiple. The price-to-book ratio is recorded at 3.16, which indicates a substantial market premium over the company's book value, reflecting investor confidence in the intangible value of its drug portfolio. Alternative valuation perspectives include a price-to-sales ratio of 3.93 and an EV/EBITDA of 18.77, metrics that suggest the company is priced at a premium relative to its sales and earnings power before interest, taxes, depreciation, and amortization. Price volatility is contextualized by a 52-week high of $36.48 and a low of $25.17, with the current trading price situated within this historical range, reflecting the stock's movement within its established annual boundaries. The beta value is 0.39, indicating that the stock price exhibits significantly lower volatility relative to the broader market, making it less sensitive to general market fluctuations.
Growth & Income
Growth metrics display a revenue decline of -10.6% year-over-year and an earnings decline of -67.0% year-over-year, implying that earnings are contracting at a much faster rate than revenue, which often points to margin compression or one-time charges affecting profitability more severely than top-line sales. As a non-dividend payer, the company does not distribute a dividend yield or maintain a payout ratio, meaning the firm reinvests its entire earnings back into research, development, and commercialization efforts to drive future growth. The overall growth and income profile is characterized by a period of contraction in both revenue and earnings, coupled with a lack of current dividend income, which positions the stock primarily for capital appreciation potential rather than current yield generation.